Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v10-EN | Version v10-EN | |
|---|---|---|
| Language | English | English |
| Date Updated | 2024-03-27 | 2024-03-27 |
| Drug Identification Number | 00402249 | 00402249 |
| Brand name | SODIUM CHLORIDE BACTERIOSTATIC INJ | SODIUM CHLORIDE BACTERIOSTATIC INJ |
| Common or Proper name | Sodium Chloride Bacteriostatic For Injection USP | Sodium Chloride Bacteriostatic For Injection USP |
| Company Name | OMEGA LABORATORIES LIMITED | OMEGA LABORATORIES LIMITED |
| Ingredients | SODIUM CHLORIDE | SODIUM CHLORIDE |
| Strength(s) | 9MG | 9MG |
| Dosage form(s) | LIQUID | LIQUID |
| Route of administration | SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR | SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR |
| Packaging size | 10 x 30mL vial / fiole | 10 x 30mL vial / fiole |
| ATC code | V07AB | V07AB |
| ATC description | ALL OTHER NON-THERAPEUTIC PRODUCTS | ALL OTHER NON-THERAPEUTIC PRODUCTS |
| Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
| Anticipated start date | 2024-02-13 | 2024-02-13 |
| Actual start date | 2024-02-13 | 2024-02-13 |
| Estimated end date | 2024-03-29 | 2024-03-29 |
| Actual end date | 2024-03-22 | 2024-03-22 |
| Shortage status | Resolved | Resolved |
| Tier 3 Status | No | No |
| Company comments | Product not available at Omega Guelph warehouse. Product available at CPDN Calgary. | Product not available at Omega Guelph warehouse. Product available at CPDN Calgary. |
| Health Canada comments |